Ignite Creation Date:
2025-12-24 @ 6:38 PM
Ignite Modification Date:
2026-02-19 @ 3:37 AM
Study NCT ID:
NCT05032157
Status:
COMPLETED
Last Update Posted:
2025-04-08
First Post:
2021-08-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Spontaneous Urticaria | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Bruton Tyrosine Kinase (BTK) inhibitor | View |
| None | Chronic Spontaneous Urticaria (CSU) | View |
| None | Urticaria Activity Score (UAS) | View |
| None | Weekly Urticaria Activity Score (UAS7) | View |
| None | Hives Severity Score (HSS) | View |
| None | Weekly Hives Severity Score (HSS7) | View |
| None | Itch Severity Score (ISS) | View |
| None | Weekly Itch Severity Score (ISS7) | View |
| None | Angioedema Activity Score (AAS) | View |
| None | Weekly Angioedema Activity Score (AAS7) | View |
| None | Dermatology Life Quality Index (DLQI) | View |